Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 11/20 | 0.40 |
| ▸ | CA2 | P00918 | 11/20 | 0.40 |
| ▸ | CA12 | O43570 | 9/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28301926 | 0.83 | CA12 (0.46) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL28038096 | 0.79 | CA1 (0.46) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL28432121 | 0.77 | MEN1 (0.42) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL28430499 | 0.77 | CA12 (0.41) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL18343872 | 0.76 | CA12 (0.44) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL18343870 | 0.76 | CA12 (0.44) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL30738873 | 0.76 | TDP1 (0.46) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL28314960 | 0.75 | CA12 (0.41) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL30745146 | 0.75 | CA12 (0.43) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL28520649 | 0.73 | CA12 (0.42) | TDP1MAOAMAOBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266954-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | Draximage, Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266953-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | Draximage, Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-7238339-B2 | Bifunctional chelating compounds containing hydroxamic acid residues | DRAXIS SPECIALTY PHARMACEUTICALS INC. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-20040086460-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | JUBILANT DRAXIMAGE INC. (CA) | 2004-05-06 | — | — | US | disclosed |
| EP-1351926-A2 | NOVEL BIFUNCTIONAL CHELATING COMPOUNDS CONTAINING HYDROXAMIC ACID RESIDUES | Draximage, Inc. (CA) | 2003-10-15 | — | — | EP | disclosed |
| US-6623721-B2 | Conjugates can be complexed to a radioisotope metallic element and used for diagnosing or treating receptor-positive tumors | DRAXIMAGE, INC. (CA) | 2003-09-23 | — | — | US | disclosed |
| WO-2002068379-A2 | NOVEL BIFUNCTIONAL CHELATING COMPOUNDS CONTAINING HYDROXAMIC ACID RESIDUES | DRAXIMAGE, INC. (CA) | 2002-09-06 | — | — | WO | disclosed |
| US-20020076377-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | JUBILANT DRAXIMAGE INC. (CA) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020076377-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | EPRS1, HAMP, PHPT1 | TDP1 2810/4885MAOA 2011/4885MAOB 2665/4885 |
| US-20040086460-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | EPRS1, HAMP, PHPT1 | TDP1 2810/4885MAOA 2011/4885MAOB 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.